C
AstraZeneca PLC
AZNCF
$149.25
-$4.24-2.76%
C
Hold
4/12/2021Downgrade
AstraZeneca PLC (AZNCF) was downgraded to C from B on 4/12/2021 due to a noticeable decline in the volatility index and total return index.
AstraZeneca PLC (AZNCF) was downgraded to C from B on 4/12/2021 due to a noticeable decline in the volatility index and total return index.
B
Buy
2/17/2021Upgraded
AstraZeneca PLC (AZNCF) was upgraded to B from C+ on 2/17/2021 due to a significant increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.49 to $0.7713, debt to equity declined from 1.98 to 1.42, and total revenue increased 12.65% from $6.58B to $7.41B.
AstraZeneca PLC (AZNCF) was upgraded to B from C+ on 2/17/2021 due to a significant increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.49 to $0.7713, debt to equity declined from 1.98 to 1.42, and total revenue increased 12.65% from $6.58B to $7.41B.
C
Hold
10/28/2020Upgraded
AstraZeneca PLC (AZNCF) was upgraded to C+ from C on 10/28/2020 due to an increase in the valuation index and dividend index.
AstraZeneca PLC (AZNCF) was upgraded to C+ from C on 10/28/2020 due to an increase in the valuation index and dividend index.
C
Hold
10/13/2020Downgrade
AstraZeneca PLC (AZNCF) was downgraded to C from C+ on 10/13/2020 due to a major decline in the total return index.
AstraZeneca PLC (AZNCF) was downgraded to C from C+ on 10/13/2020 due to a major decline in the total return index.
C
Hold
9/21/2020Upgraded
AstraZeneca PLC (AZNCF) was upgraded to C+ from C on 9/21/2020 due to a large increase in the total return index, valuation index and volatility index.
AstraZeneca PLC (AZNCF) was upgraded to C+ from C on 9/21/2020 due to a large increase in the total return index, valuation index and volatility index.
C
Hold
9/4/2020Downgrade
AstraZeneca PLC (AZNCF) was downgraded to C from C+ on 9/4/2020 due to a large decline in the total return index and efficiency index.
AstraZeneca PLC (AZNCF) was downgraded to C from C+ on 9/4/2020 due to a large decline in the total return index and efficiency index.
C
Hold
7/31/2020Upgraded
AstraZeneca PLC (AZNCF) was upgraded to C+ from C on 7/31/2020 due to a significant increase in the total return index, volatility index and efficiency index. Total capital increased 7.79% from $33.19B to $35.78B.
AstraZeneca PLC (AZNCF) was upgraded to C+ from C on 7/31/2020 due to a significant increase in the total return index, volatility index and efficiency index. Total capital increased 7.79% from $33.19B to $35.78B.
C
Hold
5/15/2017Upgraded
AstraZeneca PLC (AZNCF) was upgraded to C from C- on 5/15/2017 due to an increase in the total return index and volatility index.
AstraZeneca PLC (AZNCF) was upgraded to C from C- on 5/15/2017 due to an increase in the total return index and volatility index.
C
Hold
4/28/2017Downgrade
AstraZeneca PLC (AZNCF) was downgraded to C- from C on 4/28/2017 due to a decline in the dividend index, growth index and valuation index. Operating cash flow declined 95.51% from $1.96B to $88M, earnings per share declined from $1.45 to $0.42, and total revenue declined 3.22% from $5.59B to $5.41B.
AstraZeneca PLC (AZNCF) was downgraded to C- from C on 4/28/2017 due to a decline in the dividend index, growth index and valuation index. Operating cash flow declined 95.51% from $1.96B to $88M, earnings per share declined from $1.45 to $0.42, and total revenue declined 3.22% from $5.59B to $5.41B.
C
Hold
3/9/2017Upgraded
AstraZeneca PLC (AZNCF) was upgraded to C from C- on 3/9/2017 due to a substantial increase in the valuation index, dividend index and growth index. Operating cash flow increased 141.68% from $811M to $1.96B, and earnings per share increased from $0.8 to $1.45.
AstraZeneca PLC (AZNCF) was upgraded to C from C- on 3/9/2017 due to a substantial increase in the valuation index, dividend index and growth index. Operating cash flow increased 141.68% from $811M to $1.96B, and earnings per share increased from $0.8 to $1.45.
C
Hold
12/7/2016Downgrade
AstraZeneca PLC (AZNCF) was downgraded to C- from C on 12/7/2016 due to a decline in the total return index and volatility index.
AstraZeneca PLC (AZNCF) was downgraded to C- from C on 12/7/2016 due to a decline in the total return index and volatility index.
C
Hold
11/11/2016Upgraded
AstraZeneca PLC (AZNCF) was upgraded to C from C- on 11/11/2016 due to a major increase in the growth index, valuation index and efficiency index. Net income increased 33,900% from -$3M to $1.01B, earnings per share increased from -$0.0012 to $0.4, and operating cash flow increased 348.07% from $181M to $811M.
AstraZeneca PLC (AZNCF) was upgraded to C from C- on 11/11/2016 due to a major increase in the growth index, valuation index and efficiency index. Net income increased 33,900% from -$3M to $1.01B, earnings per share increased from -$0.0012 to $0.4, and operating cash flow increased 348.07% from $181M to $811M.
C
Hold
11/4/2016Downgrade
AstraZeneca PLC (AZNCF) was downgraded to C- from C on 11/4/2016 due to a decline in the volatility index and total return index.
AstraZeneca PLC (AZNCF) was downgraded to C- from C on 11/4/2016 due to a decline in the volatility index and total return index.
C
Hold
8/31/2016Upgraded
AstraZeneca PLC (AZNCF) was upgraded to C from C- on 8/31/2016 due to an increase in the total return index and volatility index.
AstraZeneca PLC (AZNCF) was upgraded to C from C- on 8/31/2016 due to an increase in the total return index and volatility index.
C
Hold
7/29/2016Downgrade
AstraZeneca PLC (AZNCF) was downgraded to C- from C on 7/29/2016 due to a significant decline in the volatility index, total return index and solvency index. Debt to equity increased from 1.11 to 1.31.
AstraZeneca PLC (AZNCF) was downgraded to C- from C on 7/29/2016 due to a significant decline in the volatility index, total return index and solvency index. Debt to equity increased from 1.11 to 1.31.
C
Hold
11/7/2014Downgrade
AstraZeneca PLC (AZNCF) was downgraded to C from C+ on 11/7/2014 due to a noticeable decline in the valuation index, growth index and dividend index. Earnings per share declined from $0.63 to $0.2, EBIT declined 30.8% from $1.53B to $1.06B, and operating cash flow declined 6.2% from $2.08B to $1.95B.
AstraZeneca PLC (AZNCF) was downgraded to C from C+ on 11/7/2014 due to a noticeable decline in the valuation index, growth index and dividend index. Earnings per share declined from $0.63 to $0.2, EBIT declined 30.8% from $1.53B to $1.06B, and operating cash flow declined 6.2% from $2.08B to $1.95B.
C
Hold
11/4/2014Downgrade
AstraZeneca PLC (AZNCF) was downgraded to C+ from B- on 11/4/2014 due to a noticeable decline in the volatility index and valuation index.
AstraZeneca PLC (AZNCF) was downgraded to C+ from B- on 11/4/2014 due to a noticeable decline in the volatility index and valuation index.
B
Buy
10/9/2014Upgraded
AstraZeneca PLC (AZNCF) was upgraded to B- from C+ on 10/9/2014 due to an increase in the volatility index, valuation index and total return index.
AstraZeneca PLC (AZNCF) was upgraded to B- from C+ on 10/9/2014 due to an increase in the volatility index, valuation index and total return index.
C
Hold
9/2/2014Downgrade
AstraZeneca PLC (AZNCF) was downgraded to C+ from B- on 9/2/2014 due to a decline in the valuation index and dividend index.
AstraZeneca PLC (AZNCF) was downgraded to C+ from B- on 9/2/2014 due to a decline in the valuation index and dividend index.
B
Buy
8/18/2014Upgraded
AstraZeneca PLC (AZNCF) was upgraded to B- from C+ on 8/18/2014 due to an increase in the valuation index, volatility index and dividend index.
AstraZeneca PLC (AZNCF) was upgraded to B- from C+ on 8/18/2014 due to an increase in the valuation index, volatility index and dividend index.
C
Hold
8/1/2014Upgraded
AstraZeneca PLC (AZNCF) was upgraded to C+ from C on 8/1/2014 due to a noticeable increase in the growth index, dividend index and solvency index. Operating cash flow increased 75.15% from $1.19B to $2.08B, earnings per share increased from $0.4 to $0.63, and EBIT increased 16.05% from $1.32B to $1.53B.
AstraZeneca PLC (AZNCF) was upgraded to C+ from C on 8/1/2014 due to a noticeable increase in the growth index, dividend index and solvency index. Operating cash flow increased 75.15% from $1.19B to $2.08B, earnings per share increased from $0.4 to $0.63, and EBIT increased 16.05% from $1.32B to $1.53B.
C
Hold
4/25/2014Downgrade
AstraZeneca PLC (AZNCF) was downgraded to C from B on 4/25/2014 due to a significant decline in the valuation index, growth index and solvency index. Earnings per share declined from -$0.4179 to $0.4, operating cash flow declined 52.1% from $2.48B to $1.19B, and the quick ratio declined from 1 to 0.82.
AstraZeneca PLC (AZNCF) was downgraded to C from B on 4/25/2014 due to a significant decline in the valuation index, growth index and solvency index. Earnings per share declined from -$0.4179 to $0.4, operating cash flow declined 52.1% from $2.48B to $1.19B, and the quick ratio declined from 1 to 0.82.
OTC PK
05/03/2024 11:47AM Eastern
Quotes delayed
